Organogenesis Completes PuraPly(R)AM Clinical Trial
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 06 2026
0mins
Should l Buy ORGO?
The company states: "Organogenesis Holdings announced the completion of a randomized controlled trial evaluating PuraPly(R)AM plus standard of care versus SOC alone in the management of non-healing diabetic foot ulcers. The prospective, multi-center, randomized controlled trial of 170 patients evaluated the safety and efficacy of PuraPly AM plus SOC. The trial achieved its primary endpoint, demonstrating statistically significant wound closure at 12 weeks, compared to SOC alone. These findings further demonstrate the clinical effectiveness of PuraPly(R)AM in the management of DFUs expanding the body of evidence supporting its use. Organogenesis plans to publish the study results soon in a peer-reviewed journal."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ORGO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ORGO
Wall Street analysts forecast ORGO stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 2.520
Low
9.00
Averages
9.00
High
9.00
Current: 2.520
Low
9.00
Averages
9.00
High
9.00
About ORGO
Organogenesis Holdings Inc. is a regenerative medicine company focused on the development, manufacture and commercialization of solutions for the advanced wound care and surgical and sports medicine markets. It offers a portfolio of regenerative products to address patient needs across the continuum of care. Its wound care products include Apligraf for the treatment of venous leg ulcers and diabetic foot ulcers (DFUs); Dermagraft for the treatment of DFUs; PuraPly AM as an antimicrobial barrier, cross-linked with extracellular matrix scaffold for a variety of wound types; and Affinity, Novachor and NuShield placental allografts to address a variety of wound sizes and types as a protective barrier and extracellular matrix scaffold. Its sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM and PuraPly SX for the management of open wounds in a surgical setting.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Organogenesis Completes PuraPly AM Clinical Trial for Diabetic Foot Ulcers
- Clinical Trial Success: Organogenesis has completed a randomized controlled trial for PuraPly AM in managing non-healing diabetic foot ulcers, achieving significant wound healing improvements compared to standard care, thereby supporting its application in advanced wound management.
- Product Differentiation: PuraPly AM combines a native cross-linked collagen matrix with the antimicrobial PHMB, creating a dual mechanism that effectively manages bioburden while promoting healing, enhancing its competitive edge among skin substitutes.
- Future Trial Plans: This success paves the way for PuraPly AM to advance into two large Phase 3 trials, further solidifying its potential for broader clinical adoption and driving the company's strategic growth in wound management.
- Financial Outlook: Organogenesis projects total net revenue for fiscal year 2026 to range between $350 million and $420 million, reflecting a decline of approximately 25% to 38% compared to $564.2 million in net revenue for full year 2025, indicating market challenges and necessary adjustments.
See More
Organogenesis Shares Surge 29% After Successful Clinical Trial for PuraPlyAM
- Successful Clinical Trial: Organogenesis's PuraPlyAM achieved its primary endpoint in a randomized controlled trial involving 170 patients, demonstrating statistically significant wound closure compared to standard care alone, highlighting its potential in treating diabetic foot ulcers.
- Positive Market Reaction: This announcement led to a ~29% surge in Organogenesis shares during premarket trading, reflecting increased investor confidence in the company's future prospects in regenerative medicine, which may attract more attention to its product line.
- Future Development Plans: The company intends to publish trial results in a peer-reviewed journal soon, a move that could enhance PuraPlyAM's market recognition and potentially support its inclusion in insurance coverage policies, thereby expanding its market share.
- Financial Outlook Challenges: Despite the successful clinical trial, Organogenesis faces a projected revenue decline of 25%-38% in 2026 due to CMS policy changes, indicating the company's vulnerability in a shifting market environment.
See More
Organogenesis Completes PuraPly®AM Clinical Trial with Significant Results
- Clinical Trial Success: Organogenesis's randomized controlled trial involving 170 patients demonstrated that PuraPly®AM combined with standard of care achieved statistically significant wound closure at 12 weeks (p<0.0477), further validating its clinical efficacy in managing non-healing diabetic foot ulcers.
- Future Coverage Policy Support: The publication of these trial results is expected to strongly support the inclusion of PuraPly®AM in future insurance coverage policies, emphasizing its critical role in the healing process and potentially reducing the healthcare burden on patients.
- Product Differentiation Advantage: PuraPly®AM uniquely combines a native cross-linked collagen matrix with the antimicrobial agent PHMB, effectively managing bioburden within the product and supporting healing, showcasing its distinctiveness among skin substitutes.
- Market Potential Outlook: With the growing body of clinical evidence, Organogenesis is poised to achieve significant revenue growth through PuraPly®AM, particularly in light of updated insurance policies, thereby further solidifying its market position in the regenerative medicine sector.
See More
Organogenesis Shares Surge After FDA Meeting on ReNu Approval
- Stock Surge: Organogenesis Holdings Inc. (ORGO) shares rose 7% in after-hours trading on Monday, reflecting market optimism following the company's productive meeting with the U.S. FDA.
- FDA Meeting Outcome: The company plans to initiate a rolling application for its experimental treatment ReNu by the end of December, marking a significant step forward in addressing knee osteoarthritis pain.
- Market Potential: Knee osteoarthritis is a degenerative joint disease affecting nearly 31.1 million Americans, and ReNu, a cryopreserved amniotic suspension allograft, offers anti-inflammatory, growth factor, and cellular components, indicating substantial market demand.
- Non-Surgical Alternative: ReNu provides a non-surgical treatment option aimed at reducing inflammation, alleviating pain, and enhancing joint function, potentially transforming patient treatment choices and strengthening the company's competitive position in the healthcare market.
See More
Organogenesis Completes FDA Meeting, Plans BLA Submission
- Successful FDA Meeting: Organogenesis confirmed the appropriateness of the ReNu clinical development program during a Type-B meeting with the FDA, planning to submit a rolling Biologics License Application (BLA) by the end of 2025, marking a significant advancement in regenerative medicine.
- Large-Scale Clinical Trials: The ReNu clinical development includes two large Phase 3 randomized controlled trials involving over 1,300 patients, demonstrating its potential in treating knee osteoarthritis, and if approved, it will address the growing patient demand.
- Significant Market Need: Knee osteoarthritis affects approximately 31.1 million Americans, projected to rise to 34.4 million by 2027, and the introduction of ReNu will provide new treatment options for this large patient population, improving their quality of life.
- Product Background: ReNu is a cryopreserved amniotic suspension allograft containing cellular, growth factor, and extracellular matrix components, previously marketed under Section 361 of the Public Health Service Act for about six years, showcasing a strong commercial history.
See More
Organogenesis Holdings Inc. to Begin Rolling BLA for Renu After Positive FDA Meeting
Company Overview: Organogenesis Holdings is involved in regenerative medicine, focusing on the development and commercialization of products for surgical and wound care applications.
Recent Developments: The company has successfully held a meeting to discuss future initiatives and strategies for growth in the regenerative medicine sector.
See More
Organogenesis Completes PuraPly AM Clinical Trial for Diabetic Foot Ulcers
- Clinical Trial Success: Organogenesis has completed a randomized controlled trial for PuraPly AM in managing non-healing diabetic foot ulcers, achieving significant wound healing improvements compared to standard care, thereby supporting its application in advanced wound management.
- Product Differentiation: PuraPly AM combines a native cross-linked collagen matrix with the antimicrobial PHMB, creating a dual mechanism that effectively manages bioburden while promoting healing, enhancing its competitive edge among skin substitutes.
- Future Trial Plans: This success paves the way for PuraPly AM to advance into two large Phase 3 trials, further solidifying its potential for broader clinical adoption and driving the company's strategic growth in wound management.
- Financial Outlook: Organogenesis projects total net revenue for fiscal year 2026 to range between $350 million and $420 million, reflecting a decline of approximately 25% to 38% compared to $564.2 million in net revenue for full year 2025, indicating market challenges and necessary adjustments.
See More
Organogenesis Shares Surge 29% After Successful Clinical Trial for PuraPlyAM
- Successful Clinical Trial: Organogenesis's PuraPlyAM achieved its primary endpoint in a randomized controlled trial involving 170 patients, demonstrating statistically significant wound closure compared to standard care alone, highlighting its potential in treating diabetic foot ulcers.
- Positive Market Reaction: This announcement led to a ~29% surge in Organogenesis shares during premarket trading, reflecting increased investor confidence in the company's future prospects in regenerative medicine, which may attract more attention to its product line.
- Future Development Plans: The company intends to publish trial results in a peer-reviewed journal soon, a move that could enhance PuraPlyAM's market recognition and potentially support its inclusion in insurance coverage policies, thereby expanding its market share.
- Financial Outlook Challenges: Despite the successful clinical trial, Organogenesis faces a projected revenue decline of 25%-38% in 2026 due to CMS policy changes, indicating the company's vulnerability in a shifting market environment.
See More
Organogenesis Completes PuraPly®AM Clinical Trial with Significant Results
- Clinical Trial Success: Organogenesis's randomized controlled trial involving 170 patients demonstrated that PuraPly®AM combined with standard of care achieved statistically significant wound closure at 12 weeks (p<0.0477), further validating its clinical efficacy in managing non-healing diabetic foot ulcers.
- Future Coverage Policy Support: The publication of these trial results is expected to strongly support the inclusion of PuraPly®AM in future insurance coverage policies, emphasizing its critical role in the healing process and potentially reducing the healthcare burden on patients.
- Product Differentiation Advantage: PuraPly®AM uniquely combines a native cross-linked collagen matrix with the antimicrobial agent PHMB, effectively managing bioburden within the product and supporting healing, showcasing its distinctiveness among skin substitutes.
- Market Potential Outlook: With the growing body of clinical evidence, Organogenesis is poised to achieve significant revenue growth through PuraPly®AM, particularly in light of updated insurance policies, thereby further solidifying its market position in the regenerative medicine sector.
See More
Organogenesis Shares Surge After FDA Meeting on ReNu Approval
- Stock Surge: Organogenesis Holdings Inc. (ORGO) shares rose 7% in after-hours trading on Monday, reflecting market optimism following the company's productive meeting with the U.S. FDA.
- FDA Meeting Outcome: The company plans to initiate a rolling application for its experimental treatment ReNu by the end of December, marking a significant step forward in addressing knee osteoarthritis pain.
- Market Potential: Knee osteoarthritis is a degenerative joint disease affecting nearly 31.1 million Americans, and ReNu, a cryopreserved amniotic suspension allograft, offers anti-inflammatory, growth factor, and cellular components, indicating substantial market demand.
- Non-Surgical Alternative: ReNu provides a non-surgical treatment option aimed at reducing inflammation, alleviating pain, and enhancing joint function, potentially transforming patient treatment choices and strengthening the company's competitive position in the healthcare market.
See More
Organogenesis Completes FDA Meeting, Plans BLA Submission
- Successful FDA Meeting: Organogenesis confirmed the appropriateness of the ReNu clinical development program during a Type-B meeting with the FDA, planning to submit a rolling Biologics License Application (BLA) by the end of 2025, marking a significant advancement in regenerative medicine.
- Large-Scale Clinical Trials: The ReNu clinical development includes two large Phase 3 randomized controlled trials involving over 1,300 patients, demonstrating its potential in treating knee osteoarthritis, and if approved, it will address the growing patient demand.
- Significant Market Need: Knee osteoarthritis affects approximately 31.1 million Americans, projected to rise to 34.4 million by 2027, and the introduction of ReNu will provide new treatment options for this large patient population, improving their quality of life.
- Product Background: ReNu is a cryopreserved amniotic suspension allograft containing cellular, growth factor, and extracellular matrix components, previously marketed under Section 361 of the Public Health Service Act for about six years, showcasing a strong commercial history.
See More
Organogenesis Holdings Inc. to Begin Rolling BLA for Renu After Positive FDA Meeting
Company Overview: Organogenesis Holdings is involved in regenerative medicine, focusing on the development and commercialization of products for surgical and wound care applications.
Recent Developments: The company has successfully held a meeting to discuss future initiatives and strategies for growth in the regenerative medicine sector.
See More
